ITM Establishes Subsidiary in Shanghai to Accelerate Introduction of Its Precision Oncology Portfolio in China
b"ITM AG , a leading radiopharmaceutical company, today announced the establishment of a Chinese subsidiary, ITM (Shanghai) Precision Medical Co., Ltd., in Shanghai, China.
- b"ITM AG , a leading radiopharmaceutical company, today announced the establishment of a Chinese subsidiary, ITM (Shanghai) Precision Medical Co., Ltd., in Shanghai, China.
- The new subsidiary will be part of the ITM Group as a wholly foreign-owned entity (WFOE) to further expand ITM\xe2\x80\x99s growing operations in China, which is a key emerging market for novel radiomolecular precision oncology.
- The ITM Shanghai team will especially focus on expanding and accelerating clinical development, regulatory filings and access of targeted therapeutic and diagnostic radiopharmaceuticals for Chinese patients.
- We are proud that we have been able to play a part in laying the foundation for radiomolecular precision oncology in China over the past decade.